Brain Tumours

Conclusions Need to develop and validate new response criteria e.g. RANO & RAPNO Must consider drug delivery as a vital component of neuro- oncology trials & possible reason for an active agent failing! Efficient, adaptive and flexible clinical trial designs allow study of multiple arms combination targeted therapies parallel and sequentially